GW Pharmaceuticals PLC reported Tuesday afternoon that sales of its cannabis-derived epilepsy drug more than doubled from the previous quarter, sending shares spiking more than 11% higher in after-hours trading. GW Pharmaceuticals GWPH, +10.22% reported second-quarter sales of $68.4 million for Epidiolex, which uses cannabidiol, a compound present in cannabis plants to treat certain forms of epilepsy. Wall Street […]
GW Pharmaceuticals Epidiolex
Drug Enforcement Administration Newly Classifies CBD as Schedule V Controlled Substance for Epidiolex
PRESS RELEASE DENVER, CO.—Sept. 27, 2018 Without regard for clear Congressional intent, the United States Drug Enforcement Administration (DEA) continues to act contrary to the express authorizations provided for in Section 7606 of the Agricultural Act of 2014 (the “Farm Bill”) and the Ninth Circuit Court of Appeals’ order in HIA v. DEA III (April 2018). […]
CBD is Not A Controlled Substance – The “Source Rule” Applies
An Urgent Request from Bob Hoban – Hoban Law Group As you may know, the Hoban Law Group (HLG) appeared before the Ninth Circuit Court of Appeals (in February, 2018) in San Francisco – Hemp Industry Association, et al. vs. DEA (“HIA Suit”) –concerning the issue of CBD extraction from hemp, and the legality of industrial hemp, […]
